Cargando…
Design and applications of liposome-in-gel as carriers for cancer therapy
Cancer has long been a hot research topic, and recent years have witnessed the incidence of cancer trending toward younger individuals with great socioeconomic burden. Even with surgery, therapeutic agents serve as the mainstay to combat cancer in the clinic. Intensive research on nanomaterials can...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629847/ https://www.ncbi.nlm.nih.gov/pubmed/36310364 http://dx.doi.org/10.1080/10717544.2022.2139021 |
_version_ | 1784823479073243136 |
---|---|
author | Mou, Yixuan Zhang, Pu Lai, Wing-Fu Zhang, Dahong |
author_facet | Mou, Yixuan Zhang, Pu Lai, Wing-Fu Zhang, Dahong |
author_sort | Mou, Yixuan |
collection | PubMed |
description | Cancer has long been a hot research topic, and recent years have witnessed the incidence of cancer trending toward younger individuals with great socioeconomic burden. Even with surgery, therapeutic agents serve as the mainstay to combat cancer in the clinic. Intensive research on nanomaterials can overcome the shortcomings of conventional drug delivery approaches, such as the lack of selectivity for targeted regions, poor stability against degradation, and uncontrolled drug release behavior. Over the years, different types of drug carriers have been developed for cancer therapy. One of these is liposome-in-gel (LP–Gel), which has combined the merits of both liposomes and hydrogels, and has emerged as a versatile carrier for cancer therapy. LP–Gel hybrids have addressed the lack of stability of conventional liposomes against pH and ionic strength while displaying higher efficiency of delivery hydrophilic drugs as compared to conventional gels. They can be classified into three types according to their assembled structure, are characterized by their nontoxicity, biodegradability, and flexibility for clinical use, and can be mainly categorized based on their controlled release, transmucosal delivery, and transdermal delivery properties for anticancer therapy. This review covers the recent progress on the applications of LP–Gel hybrids for anticancer therapy. |
format | Online Article Text |
id | pubmed-9629847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-96298472022-11-03 Design and applications of liposome-in-gel as carriers for cancer therapy Mou, Yixuan Zhang, Pu Lai, Wing-Fu Zhang, Dahong Drug Deliv Research Article Cancer has long been a hot research topic, and recent years have witnessed the incidence of cancer trending toward younger individuals with great socioeconomic burden. Even with surgery, therapeutic agents serve as the mainstay to combat cancer in the clinic. Intensive research on nanomaterials can overcome the shortcomings of conventional drug delivery approaches, such as the lack of selectivity for targeted regions, poor stability against degradation, and uncontrolled drug release behavior. Over the years, different types of drug carriers have been developed for cancer therapy. One of these is liposome-in-gel (LP–Gel), which has combined the merits of both liposomes and hydrogels, and has emerged as a versatile carrier for cancer therapy. LP–Gel hybrids have addressed the lack of stability of conventional liposomes against pH and ionic strength while displaying higher efficiency of delivery hydrophilic drugs as compared to conventional gels. They can be classified into three types according to their assembled structure, are characterized by their nontoxicity, biodegradability, and flexibility for clinical use, and can be mainly categorized based on their controlled release, transmucosal delivery, and transdermal delivery properties for anticancer therapy. This review covers the recent progress on the applications of LP–Gel hybrids for anticancer therapy. Taylor & Francis 2022-10-30 /pmc/articles/PMC9629847/ /pubmed/36310364 http://dx.doi.org/10.1080/10717544.2022.2139021 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Mou, Yixuan Zhang, Pu Lai, Wing-Fu Zhang, Dahong Design and applications of liposome-in-gel as carriers for cancer therapy |
title | Design and applications of liposome-in-gel as carriers for cancer therapy |
title_full | Design and applications of liposome-in-gel as carriers for cancer therapy |
title_fullStr | Design and applications of liposome-in-gel as carriers for cancer therapy |
title_full_unstemmed | Design and applications of liposome-in-gel as carriers for cancer therapy |
title_short | Design and applications of liposome-in-gel as carriers for cancer therapy |
title_sort | design and applications of liposome-in-gel as carriers for cancer therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629847/ https://www.ncbi.nlm.nih.gov/pubmed/36310364 http://dx.doi.org/10.1080/10717544.2022.2139021 |
work_keys_str_mv | AT mouyixuan designandapplicationsofliposomeingelascarriersforcancertherapy AT zhangpu designandapplicationsofliposomeingelascarriersforcancertherapy AT laiwingfu designandapplicationsofliposomeingelascarriersforcancertherapy AT zhangdahong designandapplicationsofliposomeingelascarriersforcancertherapy |